Acute-on-Chronic Liver Failure (ACLF): Management Guidelines & Evidence

1. Definition and Classification

• ACLF Grade 1: 1 organ failure (kidney OR other organ + creatinine 1.5-1.9 OR HE grade 1-2)
• ACLF Grade 2: 2 organ failures
• ACLF Grade 3: 3 or more organ failures (>90-day mortality exceeds 90%)

2. Precipitating Events - Identify and Treat

3. Core Management Principles

A. Identify Precipitant and Provide Specific Treatment

• Infection: Screen thoroughly (blood cultures, ascitic fluid, urine, chest imaging). Broad-spectrum antibiotics should be initiated immediately in the ER - delay beyond 12-24 hours significantly increases mortality (2025 AASLD Liver Meeting data). Antibiotic choice guided by local resistance patterns.
• Alcohol-associated hepatitis: Prednisolone 40 mg/day for 28 days IF no contraindication (infection, GI bleed, renal failure). Response assessed with Lille score at Day 7. Glucocorticoid response rate drops from ~52% in ACLF Grade 1 to only ~8% in ACLF Grade 3.
• HBV reactivation: Entecavir or tenofovir immediately.
• GI bleeding: Standard variceal management (octreotide/terlipressin + endoscopy + antibiotics).

B. ICU-Level Organ Support

C. Albumin

• Albumin 1.5 g/kg on Day 1, then 1 g/kg on Day 3 for SBP (established benefit, reduces AKI and mortality).
• Long-term albumin infusions for non-SBP indications - benefit remains under evaluation (AGA 2024 expert review).

4. Extracorporeal Liver Support

Plasma Exchange (PE)

• PE significantly associated with higher 30-day survival (RR 1.36, 95% CI 1.22-1.52, p<0.001)
• Higher 90-day survival (RR 1.21, 95% CI 1.10-1.34, p<0.001)
• Caveat: On RCT-only subgroup analysis, survival benefit was not significant; most data from observational studies, predominantly Asian cohorts.
• Role: Bridge to liver transplantation or for non-transplant candidates. Chinese 2025 guidelines and APASL support its use as artificial liver support (Grade 1A for bridging).

Other Extracorporeal Systems (MARS, PROMETHEUS)

• No survival benefit shown in RCTs to date.
• Can be used as bridge to transplantation in select cases.
• Evidence remains limited; emerging but not yet standard.

5. Liver Transplantation

Scoring for Transplant Prioritization

• ACLF Type I (no extrahepatic organ failure): MELD score guides eligibility.
• ACLF Type II (with extrahepatic organ failure): CLIF-C ACLF score recommended for combined assessment.
• Reassess severity every 3-7 days dynamically.

Decision Framework (2025 Chinese Guidelines / EASL-CLIF aligned)

Contraindications / Risk Factors for Poor Post-LT Outcome

• Clinical Frailty Scale score ≥7 (prior to ICU admission) - considered contraindication per international expert consensus
• Age >60, diabetes, obesity, cardiovascular disease
• Severe ARDS or non-reconstructable coronary artery disease
• Portal vein thrombosis, poor performance status

Alcohol-Related ACLF and Transplant

• Traditional 6-month abstinence rule may be fatal in ACLF.
• EASL 2024 LT Guidelines (PMID 39487043): LT can be considered despite active/recent alcohol use IF: no prior known liver disease, absence of psychiatric comorbidities, presence of supportive family network. Requires thorough psychosocial and multidisciplinary assessment.

6. Prognosis and Monitoring

• 90-day mortality with 3+ organ failures managed in ICU exceeds 90% (Sleisenger & Fordtran).
• SOFA score is more prognostically accurate than Child-Pugh or MELD in ICU patients.
• Dynamic reassessment at 4-week and 12-week intervals (beyond single time-point scores) is emerging as the best prognostic framework (2025 Chinese Guidelines, Grade 1B).

7. Current Guideline Summary

• AASLD emphasizes early liver transplantation and intensive care.
• APASL advocates aggressive medical management including liver regeneration therapies, more relevant in resource-limited settings where LT is less accessible.

8. Emerging Therapies Under Investigation

• Granulocyte-colony stimulating factor (G-CSF): Liver regeneration; some positive data from Asian RCTs, not yet standard in Western guidelines.
• Immune-modulating therapies: Targeting toll-like receptor signaling and systemic inflammation.
• Fecal microbiota transplantation: Gut-liver axis modulation; early-phase evidence.
• Novel extracorporeal systems: TAM core, SALT-M model for transplant candidate selection.

Medical Management of ACLF: Evidence-Based Review

Framework: The Three Pillars

1. Identify and treat the precipitating event
2. Organ-specific supportive care
3. Bridge to liver transplantation or recovery

1. Infection Management

Evidence

Recommendations

• Empirical broad-spectrum antibiotics immediately on presentation, before culture results - do not wait.
• Choice guided by local antibiogram and likely source (SBP: cefotaxime/ceftriaxone; hospital-acquired/MDR risk: piperacillin-tazobactam or carbapenem).
• Screen all body compartments: blood cultures (2 sets), ascitic fluid (cell count + culture), urine, respiratory secretions.
• Antifungal coverage (fluconazole or echinocandin) if fungal infection suspected or no bacterial source found with clinical deterioration.
• Daily reassessment and de-escalation based on culture results.
• Norfloxacin or trimethoprim-sulfamethoxazole for SBP prophylaxis in high-risk patients (Child-Pugh C, low ascitic protein <15 g/L).

Caveat

2. Albumin

Evidence

• HAS significantly reduced overall odds of death vs. alternatives: pooled OR 0.769 (95% CI 0.652-0.908), p=0.0019
• Reduced renal dysfunction and recurrent ascites
• Caveat: benefits primarily seen in smaller, lower-quality trials; large well-designed RCTs still needed

Guideline-Backed Indications

Caution in ACLF

3. Acute Kidney Injury (AKI) / Hepatorenal Syndrome (HRS-AKI)

Step-wise Management

1. Stop nephrotoxins (NSAIDs, aminoglycosides, contrast, diuretics)
2. Volume resuscitation: albumin 1 g/kg/day (max 100g) x 2 days to exclude pre-renal AKI
3. Diagnose HRS after ruling out other AKI causes, if urine output ≤0.5 mL/kg for ≥6h + no improvement in creatinine within 24-48h after volume challenge

Vasoconstrictors for HRS-AKI

• A 2025 RCT post-hoc analysis of the CONFIRM trial (Rockey et al., Liver Int, PMID 41200852) showed:
  • HRS reversal: 43% terlipressin vs 17% placebo (p<0.001) in ACLF Grade 1-2 patients
  • Significant reductions in serum creatinine (p<0.001)
  • Important: Terlipressin is significantly less effective in ACLF Grade 3 and is associated with increased colonization by multidrug-resistant bacteria
  • The FDA label mandates caution in ACLF Grade 3 due to risk of respiratory failure
  • Terlipressin dose: 2-12 mg/day (IV bolus or continuous infusion)
• Norepinephrine (0.5-3 mg/h) is an alternative in ICU settings, with comparable efficacy.

1. Renal Replacement Therapy (RRT): initiated if pharmacotherapy fails (persistent oliguria, refractory hyperkalemia, severe metabolic acidosis, or uremia).

4. Circulatory Failure

• Defined by vasopressor requirement (EASL-CLIF criteria)
• Pathophysiology: systemic inflammation → reduced vascular resistance → arterial hypotension
• First-line vasopressor: Norepinephrine
• Adrenal insufficiency is frequently found in critically ill ACLF; the AASLD 2024 guideline recommends routine screening (short synacthen test) in all ACLF patients with circulatory failure
  • If confirmed: Hydrocortisone 200 mg/day IV (50 mg q6h)
• Volume management: balanced - avoid over-hydration (risk of pulmonary edema) and under-resuscitation

5. Hepatic Encephalopathy (HE)

• No difference in development of ACLF (17.9% vs 14.2%, HR 1.23, p=0.52)
• No reduction in transplant-free death or cirrhosis complications
• 3 patients (2.6%) developed rhabdomyolysis in the treatment arm
• Conclusion: simvastatin + rifaximin does NOT prevent ACLF development

6. Coagulopathy Management

• Do NOT routinely correct coagulopathy (INR does not reflect hemostatic balance - both pro- and anti-coagulant factors are depleted equally in cirrhosis)
• ACG guideline and AASLD: correct only for active bleeding or invasive procedures
• Platelet transfusion threshold: >50,000 for procedures; >20,000 for severe spontaneous bleeding
• FFP: avoid prophylactically (worsens portal hypertension, no survival benefit)
• Vitamin K: give IV once to all patients with coagulopathy to exclude deficiency

7. Granulocyte Colony-Stimulating Factor (G-CSF)

Evidence

• Dose: Typically 5 mcg/kg/day SC for 5 consecutive days (Indian trials)
• Mechanism: Promotes hepatic regeneration via mobilization of CD34+ stem cells, reduces systemic inflammation
• Limitation: Most studies from Asian centres (primarily HBV-ACLF); less evidence in Western (alcohol-related) ACLF; not yet endorsed in EASL or AASLD guidelines
• Status: Recommended in APASL/AARC Kyoto Consensus 2025 as hepatic regenerative therapy; promising but not yet standard in Western practice

8. Alcohol-Associated Hepatitis (AH) as Precipitant

• Severe AH (Maddrey discriminant function ≥32 or MELD >20): consider prednisolone 40 mg/day for 28 days
• Assess response with Lille score at Day 7:
  • Lille ≥0.45: non-responder - stop steroids
  • Lille <0.45: responder - complete 28-day course
• Steroid response rate decreases dramatically with ACLF severity: ~52% in ACLF Grade 1 vs only 8% in ACLF Grade 3
• Infection incidence with steroids: ~33% - screen and treat infections before starting
• Contraindications: active infection, GI bleeding, renal failure (creatinine >2.5 mg/dL), hepatitis B

9. Extracorporeal Liver Support Systems

Evidence

• Greater benefit in patients with lower MELD scores and lower total bilirubin
• Plasma Exchange (PE): 2024 meta-analysis (Beran et al., PMID 37530812) - significantly higher 30-day survival (RR 1.36, 95% CI 1.22-1.52) and 90-day survival (RR 1.21, 95% CI 1.10-1.34) in ACLF vs. standard therapy
  • Note: on RCT-only subgroup, benefit was not statistically significant - most evidence from observational data
• DIALIVE device (RCT): reduced inflammatory markers and faster ACLF resolution but no difference in 28-day mortality
• MARS and PROMETHEUS: not shown to improve survival in major RCTs
• Current role: bridge to LT or for non-transplant candidates - not yet routine standard of care

10. Mesenchymal Stem Cell (MSC) Therapy

• MSC infusion significantly decreased MELD score at 4 weeks and 24 weeks
• Improved albumin levels at 4 and 24 weeks
• Reduced INR and ALT levels
• No increase in adverse events or serious adverse events
• Status: Experimental; not yet guideline-endorsed; primarily studied in HBV-ACLF in Asian populations; larger RCTs with longer follow-up needed

11. HBV-Associated ACLF

• Nucleoside/nucleotide analogues immediately: Entecavir 0.5 mg/day or Tenofovir 300 mg/day
• A 2025 network meta-analysis (Hua et al., Medicine, PMID 41430999) evaluated different therapeutic methods for HBV-ACLF 90-day prognosis - antivirals + immunomodulatory therapy ranked highly
• Do NOT use interferon in this setting (precipitates worsening)

12. Nutritional Support

• 35 kcal/kg/day total energy; 1.2-1.5 g protein/kg/day (do NOT restrict protein - older dogma)
• Frequent small meals + bedtime carbohydrate snack to minimize overnight fasting catabolism
• Enteral nutrition preferred over parenteral whenever gut is functioning
• Supplement fat-soluble vitamins (A, D, E, K) and zinc if deficient

Summary: Evidence Level for Key Interventions

Evidence for LOLA, Lactulose, and Rifaximin in Hepatic Encephalopathy / ACLF

Background: The Ammonia-HE Pathway

1. LACTULOSE

Mechanism and Dosing

• Oral or rectal; non-absorbable → reaches distal ileum/colon → fermented by bacteria to short-chain fatty acids → lowers luminal pH → converts NH4+ to NH3+ (non-absorbable) + eradicates gram-negative bacteria
• Dose: 15-30 mL orally twice daily, titrated to 2-3 soft bowel movements per day
• Acute severe HE: hourly 30-45 mL to induce rapid improvement; symptoms can abate in 24-48 hours
• Rectal administration (retention enema) when oral route not feasible (coma, aspiration risk)

Evidence Summary

• First-line treatment for episodic overt HE - endorsed in EASL, AASLD, ACG, and Goldman-Cecil guidelines
• ACG 2026 HE Guideline: Strong recommendation, high certainty for lactulose as first-line OHE therapy and maintenance prophylaxis after first episode
• Quality of life: A 2023 meta-analysis (Moon et al., Am J Gastroenterol, PMID 36730910) of 16 studies (1,376 patients) found lactulose significantly improved health-related quality of life in covert HE (Sickness Impact Profile pooled MD 6.92, 95% CI 6.66-7.18)

Limitations / Cautions

• Overuse causes dehydration and electrolyte abnormalities, which themselves precipitate/worsen HE - a critical pitfall in ACLF
• Diarrhea, flatulence, abdominal cramping common
• In ACLF with ileus risk: polyethylene glycol (PEG) 3350 (4L over 4h) may produce faster clinical response with less risk
• Serum ammonia should NOT guide dosing or treatment decisions (ACG 2026 guideline)

2. RIFAXIMIN

Mechanism and Dosing

• Minimally absorbed (<0.4%) macrolide antibiotic - acts entirely within the gut lumen
• Broad-spectrum activity against gram-positive, gram-negative, aerobic, anaerobic organisms
• Reduces urease-producing bacteria → reduces ammonia generation + reduces gut-derived endotoxins (reduces systemic inflammation)
• Standard dose: 550 mg twice daily
• Also improves systemic hemodynamics and kidney function in cirrhosis via gut decontamination (important in ACLF context - National Kidney Foundation textbook)

Evidence Summary

For Prophylaxis of HE (Primary and Secondary)

Combination (Rifaximin + Lactulose) vs. Lactulose Alone

• Higher effective rate: RR 1.30 (95% CI 1.10-1.53, p=0.002)
• Reduced mortality: RR 0.57 (95% CI 0.41-0.80, p=0.001)
• Textbook confirmation (Mulholland & Greenfield's Surgery): rifaximin + lactulose vs. lactulose + placebo showed complete HE reversal in 76% vs. 50.8% and reduced mortality (23.1% vs. 49.1%)

Phase 3 RCT (2024): HE Recurrence Prevention

• Note: this paper carries an erratum (PMID 38934704)

Patient-Reported Outcomes

Guideline Positions on Rifaximin

3. LOLA (L-Ornithine L-Aspartate)

Mechanism

• Ornithine: substrate for ornithine transcarbamylase (OTC) and carbamoyl phosphate synthetase → activates urea cycle in periportal hepatocytes
• Aspartate: fuels the urea cycle in perivenous hepatocytes; also substrate for glutamine synthetase in skeletal muscle → increases muscular ammonia detoxification
• Reduces blood ammonia AND inflammatory cytokines (TNF-α, IL-6) - dual anti-ammonia and anti-inflammatory mechanism
• Not available in the USA (Sleisenger & Fordtran); used widely in Asia, Europe, and India

Evidence Summary

Landmark RCT (Double-Blind, Hepatology 2022)

• Design: 140 patients with cirrhosis + overt HE Grade III-IV, double-blind RCT
• Intervention: IV LOLA 30 g/24h x 5 days + lactulose + rifaximin vs. placebo + lactulose + rifaximin
• Results:

IV vs. Oral LOLA (RCT 2024)

• Both routes caused significant ammonia reduction (p<0.001 within each group)
• No significant difference between IV and oral routes (p=0.511)
• Oral LOLA is an effective alternative to IV LOLA

Meta-Analysis: LOLA + Lactulose vs. Lactulose Alone

• LOLA + lactulose: 31% more effective than lactulose alone (RR 1.31, 95% CI 1.22-1.42, p=0.00001)
• Significantly reduced AST, ALT, TBIL, and NH3 (all p=0.00001)
• Combination is consistently superior to lactulose monotherapy

Meta-Analysis: LOLA for Minimal HE (MHE)

• LOLA vs. placebo: Reversal of MHE RR 2.264 (95% CI 1.528-3.352)
• Prevention of OHE progression: RR 0.220 (95% CI 0.076-0.637, p=0.005)
• Oral LOLA more effective for MHE reversal than IV
• Did NOT reduce mortality in MHE population (RR 0.422, NS) - benefit is in overt/severe HE

Cochrane Review Finding

4. Evidence Specifically in ACLF Context

• Lactulose: First-line in ACLF HE; oral or rectal. ACLF management guidelines uniformly recommend it. Risk of over-administration causing AKI/electrolyte imbalance in critically ill patients - careful titration mandatory.
• Rifaximin: In ACLF, benefits extend beyond HE - gut decontamination improves systemic hemodynamics and kidney function (National Kidney Foundation textbook); norfloxacin/rifaximin reduces HRS risk independent of SBP prevention. AASLD 2024 remains cautious about rifaximin in acute ACLF (evidence unclear); SCCM gives a conditional recommendation.
• LOLA (IV): The Jain et al. Hepatology 2022 RCT directly included cirrhotic patients with Grade III-IV HE - highly relevant to ACLF. A 2025 ACLF management review (PMC12467013) states: "LOLA 30g/24h combined with lactulose and rifaximin was more effective than lactulose and rifaximin alone in improving HE grades, recovery time, and 28-day survival." However, clinical efficacy of LOLA in ACLF "remains a subject of ongoing debate."

5. Practical Algorithm in ACLF with HE

Overt HE in ACLF
      ↓
1. Identify & treat precipitants (infection, GI bleed, constipation, drugs)
      ↓
2. LACTULOSE (oral 15-30 mL 2-4x/day or rectal enema)
   - Target 2-3 soft bowel movements/day
   - Use PEG if ileus risk
      ↓
3. If no improvement in 24-48h OR Grade III-IV HE:
   ADD RIFAXIMIN 550 mg BD
      ↓
4. Severe HE (Grade III-IV) - especially in ACLF:
   ADD IV LOLA 30 g/24h over 5 days
      ↓
5. Airway protection (intubate if aspiration risk, Grade III-IV)
6. Avoid protein restriction (1.2-1.5 g/kg/day maintained)
7. If Grade III+ persists: consider MARS (extracorporeal albumin dialysis)

6. Evidence Quality Summary

The CANONIC Study: The Landmark That Defined ACLF

Overview

Study Design

The CLIF-SOFA Score: What CANONIC Created

ACLF Definition from CANONIC

Key Findings

1. Prevalence

• 303/1,343 patients (22.6%) had ACLF at study enrollment
• A further 112 patients (8.3%) developed ACLF during hospitalization
• 928 (69.1%) had acute decompensation without ACLF

2. ACLF vs. Simple Acute Decompensation - Distinguishing Features

3. Predictors of Mortality in ACLF

• Higher CLIF-SOFA score (p<0.001)
• Higher leukocyte count (p<0.001) - highlighting systemic inflammation as a driver, not just organ failure per se

4. First-vs-Prior Decompensation: A Surprising Finding

• Higher number of organ failures
• Higher leukocyte counts
• Higher mortality

Downstream CANONIC Sub-Studies

1. CLIF-C ACLF Score Development (Jalan et al., J Hepatol 2014, PMID 24950482)

• CLIF-C Organ Failure (OF) score
• Age
• White blood cell count

Patients with ≥4 organ failures or CLIF-C ACLF score >64 at Days 3-7 who did not receive liver transplantation had 100% 28-day mortality → rational basis for intensive care discontinuation

2. Clinical Course Study (Gustot et al., Hepatology 2015, PMID 25877702)

• 49.2% had resolution or improvement of ACLF
• 30.4% had a steady or fluctuating course
• 20.4% worsened

• 81% of patients reached their final ACLF grade by day 7 → making the Day 3-7 assessment the critical window for treatment decisions
• Among patients who received early liver transplantation: 75% survived at least 1 year

3. Systemic Inflammation Sub-Study (Clària et al., Hepatology 2016, PMID 27483394)

• Patients with ACLF had significantly higher cytokines (TNF-α, IL-6, IL-1β, etc.) and oxidative stress markers (HNA2 - redox state of albumin) than those without ACLF
• Different cytokine profiles by precipitant: alcohol/AH-precipitated ACLF vs. bacterial infection-precipitated ACLF vs. other
• Severity of systemic inflammation (SI) was more strongly associated with ACLF than haemodynamic dysfunction
• Conclusion: Established systemic inflammation as the primary driver of ACLF (the "SI hypothesis"), not merely portal hypertension or haemodynamic failure - a paradigm shift

4. Hyponatraemia Sub-Study (Cárdenas et al., Crit Care 2014, PMID 25643318)

• Hyponatraemia (Na <130 mEq/L) independently predicted worse outcomes in ACLF
• Added prognostic value beyond organ failure grading

Legacy and Impact

Summary in One Paragraph